Home/Eli Lilly/Daniel M. Skovronsky
DM

Daniel M. Skovronsky

Chief Scientific and Medical Officer, President of Lilly Research Laboratories

Eli Lilly

Eli Lilly Pipeline

DrugIndicationPhase
Tirzepatide (Mounjaro)Type 2 DiabetesApproved
Tirzepatide (Zepbound)ObesityApproved
DonanemabAlzheimer's DiseasePhase 3
MirikizumabUlcerative ColitisPhase 3
LebrikizumabAtopic DermatitisPhase 3
OrforglipronType 2 DiabetesPhase 3
PirtobrutinibB-cell MalignanciesPhase 3
RetifanlimabVarious CancersPhase 2/3